Skip to main content

Danish Firm Nuevolution Lends Screening Technology to Epigenetics Therapeutics Project

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Danish drug discovery firm Nuevolution today said it will employ its screening technology as part of a consortium to identify and develop small molecule drugs against epigenetic disorders.

Nuevolution, based in Copenhagen, Denmark, joins the consortium that also includes EpiTherapeutics, ExpreS2ion Biotechnologies, and the research group of Kristian Helin at the Biotech Research & Innovation Centre at the University of Copenhagen.

For the collaboration, Nuevolution will use its Chemetics high-throughput and fragment-based screening technology to screen hundreds of millions of small molecules, it said in a statement. The Chemetics platform enables rapid synthesis and DNA tagging of hundreds of millions of chemically diverse drug-like small molecule compounds, said Nuevolution.

The other members will provide biology and disease expertise.

The DKK24 million ($4.5 million) project is being funded by the Danish High Technology Fund.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.